Streamlined Fragment-Based Discovery Platform for Targeting Structured RNAs
Fragment-based drug discovery typically relies on specialized spectrometric methods to identify low-affinity compounds that bind to biomolecules. Here, we report a proof-of-concept study on the development of a streamlined fragment-based screening platform for small molecules targeting RNA. This method employs low molecular weight fragments appended with a diazirine reactive moiety and an alkyne tag. Upon photolysis and click chemistry with an azide-containing fluorophore, these compounds can be visualized for binding to the r(CUG) repeat expansion [r(CUG)<sup>exp</sup>] implicated in myotonic dystrophy type 1 (DM1). Fragments were found to bind the 1 × 1 nucleotide U/U internal loops formed when r(CUG)<sup>exp</sup> folds, guiding the design of homodimeric compounds capable of interacting with adjacent internal loops in a single molecule. One dimeric compound exhibited enhanced affinity and was converted into a proximity-induced covalent binder for prolonged target occupancy. This work establishes a versatile platform for targeting structured RNAs with potential applications across a variety of disease-relevant RNA targets.
Authors
- Matthew D. Disney (ORCID: https://orcid.org/0000-0001-8486-1796)
- Amirhossein Taghavi (ORCID: https://orcid.org/0000-0001-9270-9145)
- Yilin Jia (ORCID: https://orcid.org/0000-0002-2284-4250)
- Patrick R. A. Zanon (ORCID: https://orcid.org/0000-0002-8883-8275)
Institutions
- Scripps Research Institute (US)
- Scripps (United States) (US)
Publication Details
- Journal
- ACS Chemical Biology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1021/acschembio.5c00372
- Citations
- 2
- Primary Topic
- RNA and protein synthesis mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Muscular Dystrophy Association
- Deutsche Forschungsgemeinschaft
- National Institute of Neurological Disorders and Stroke